Potent orally active allosteric inhibitors of SHP2 have been reported [13] and are currently being evaluated in phases I/II trials that focus on advanced solid tumors, mostly in non-small cell lung cancer (NSCLC), squamous cell carcinoma (SCC) or colorectal cancer (CRC) [14] (NCT03114319). Here, PTPN11 is linked to non-small cell lung carcinoma.